Digestive Diseases and Sciences

, Volume 64, Issue 2, pp 591–593 | Cite as

Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis

  • Costanza De Maria
  • Ilaria Ghidotti
  • Federica Grillo
  • Edoardo G. GianniniEmail author
Case Report


Hepatitis C virus (HCV) infection has been linked to the development of autoimmunity, in part through activation of B cells, which also plays a pathogenic role in autoimmune diseases of the liver [1]. Since excessive immune response against HCV may promote autoimmunity, it is reasonable to consider this added benefit of HCV eradication by direct-acting antiviral (DAA), although there may be concerns related to recent reports of DAA-induced AIH in patients treated for HCV [2]. Here, we describe the case of a patient with chronic HCV infection and AIH who was successfully treated with DAA, and who showed a considerable improvement in global liver function after viral clearance.

Case Report

A 64-year-old woman with chronic, untreated HCV infection (genotype 2) for 23 years was referred to our unit 5 years ago due to an acute hepatitis flare (aminotransferases 10 times the upper limit). At referral, laboratory work-up also showed elevated gammaglobulin, and positive...


Autoimmune hepatitis Azathioprine Hepatitis C virus Cirrhosis Direct-acting antivirals Outcome 


Compliance with ethical standards

Conflict of interest

No financial support was received for this study. The author has no personal interests to declare.

Informed consent

Informed consent was obtained from the patient. No IRB approval is required at our institution for case reports.


  1. 1.
    Czaja AJ. Under-evaluated or unassessed pathogenic pathways in autoimmune hepatitis and implications for future management. Dig Dis Sci. 2018;63:1706–1725. Scholar
  2. 2.
    Matsumoto K, Kikuchi K, Kajiyama Y, et al. Development of autoimmune hepatitis during direct-acting antiviral therapy for chronic hepatitis C virus infection: a case report. Intern Med. 2018;57:2669–2673.CrossRefGoogle Scholar
  3. 3.
    Stewart RA, MacDonald BR, Chu TC, et al. Ledipasvir/sofosbuvir effectively treats hepatitis C virus infections in an underserved population. Dig Dis Sci. 2018. Scholar
  4. 4.
    Sugiura A, Wada S, Mori H, et al. Successful treatment for chronic hepatitis C-autoimmune hepatitis overlap syndrome due to daclatasvir and asunaprevir. Case Rep Gastroenterol. 2017;11:305–311.CrossRefGoogle Scholar
  5. 5.
    Giannini EG, Basso M, Savarino V, et al. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther. 2010;31:502–508.CrossRefGoogle Scholar
  6. 6.
    Dever JB, Ducom JH, Ma A, et al. Engagement in care of high-risk hepatitis C patients with interferon-free direct-acting antiviral therapies. Dig Dis Sci. 2017;62:1472–1479. CrossRefGoogle Scholar
  7. 7.
    Bouma G, van Nieuwkerk CM. Treatment withdrawal in autoimmune hepatitis. Dig Dis. 2015;33:88–93.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Costanza De Maria
    • 1
    • 2
  • Ilaria Ghidotti
    • 1
    • 2
  • Federica Grillo
    • 2
    • 3
  • Edoardo G. Giannini
    • 1
    • 2
    Email author
  1. 1.Gastroenterology Unit, Department of Internal MedicineUniversity of GenoaGenoaItaly
  2. 2.Ospedale Policlinico San Martino – IRCCS per l’OncologiaGenoaItaly
  3. 3.Pathology Unit, Department of Surgical SciencesUniversity of GenoaGenoaItaly

Personalised recommendations